Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance

S. T. Gancher, John Nutt, William Woodward

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

We assessed the clinical utility of apomorphine infusional therapy in patients with parkinsonism and motor fluctuations and sought evidence for alterations in drug response resulting from chronic treatment. Six patients with Parkinson's disease were treated for 3 months with s.c. infusions of apomorphine administered during waking hours. At the beginning and the end of the study, test doses of apomorphine (12.5-100 μg/kg) were administered to establish a dose-response curve. Over the study, the patients reported a significant improvement in the number of 'on' hours experienced per day and substantially reduced the dose and frequency of levodopa and other antiparkinsonian medications. No average change in apomorphine dose-response relationships or pharmacokinetics was observed during the study. However, two patients lowered the infusion rate during the 3-month observation and exhibited higher drug levels and longer responses following test doses of apomorphine given at the end of the study. Although pragmatic concerns with the use of infusion pumps solutions and adverse effects limited the overall benefit afforded by the treatment, this kind of drug treatment may be useful in selected patients with severe parkinsonism and fluctuations.

Original languageEnglish (US)
Pages (from-to)37-43
Number of pages7
JournalMovement Disorders
Volume10
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Apomorphine
Parkinson Disease
Parkinsonian Disorders
Pharmaceutical Preparations
Antiparkinson Agents
Therapeutics
Infusion Pumps
Levodopa
Pharmacokinetics
Observation

Keywords

  • Apomorhine
  • Infusional therapy
  • Parkinson's disease
  • Sensitization
  • Tolerance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Apomorphine infusional therapy in Parkinson's disease : Clinical utility and lack of tolerance. / Gancher, S. T.; Nutt, John; Woodward, William.

In: Movement Disorders, Vol. 10, No. 1, 1995, p. 37-43.

Research output: Contribution to journalArticle

@article{6a112f36ba934cb7b79b018d343c01ea,
title = "Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance",
abstract = "We assessed the clinical utility of apomorphine infusional therapy in patients with parkinsonism and motor fluctuations and sought evidence for alterations in drug response resulting from chronic treatment. Six patients with Parkinson's disease were treated for 3 months with s.c. infusions of apomorphine administered during waking hours. At the beginning and the end of the study, test doses of apomorphine (12.5-100 μg/kg) were administered to establish a dose-response curve. Over the study, the patients reported a significant improvement in the number of 'on' hours experienced per day and substantially reduced the dose and frequency of levodopa and other antiparkinsonian medications. No average change in apomorphine dose-response relationships or pharmacokinetics was observed during the study. However, two patients lowered the infusion rate during the 3-month observation and exhibited higher drug levels and longer responses following test doses of apomorphine given at the end of the study. Although pragmatic concerns with the use of infusion pumps solutions and adverse effects limited the overall benefit afforded by the treatment, this kind of drug treatment may be useful in selected patients with severe parkinsonism and fluctuations.",
keywords = "Apomorhine, Infusional therapy, Parkinson's disease, Sensitization, Tolerance",
author = "Gancher, {S. T.} and John Nutt and William Woodward",
year = "1995",
doi = "10.1002/mds.870100108",
language = "English (US)",
volume = "10",
pages = "37--43",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Apomorphine infusional therapy in Parkinson's disease

T2 - Clinical utility and lack of tolerance

AU - Gancher, S. T.

AU - Nutt, John

AU - Woodward, William

PY - 1995

Y1 - 1995

N2 - We assessed the clinical utility of apomorphine infusional therapy in patients with parkinsonism and motor fluctuations and sought evidence for alterations in drug response resulting from chronic treatment. Six patients with Parkinson's disease were treated for 3 months with s.c. infusions of apomorphine administered during waking hours. At the beginning and the end of the study, test doses of apomorphine (12.5-100 μg/kg) were administered to establish a dose-response curve. Over the study, the patients reported a significant improvement in the number of 'on' hours experienced per day and substantially reduced the dose and frequency of levodopa and other antiparkinsonian medications. No average change in apomorphine dose-response relationships or pharmacokinetics was observed during the study. However, two patients lowered the infusion rate during the 3-month observation and exhibited higher drug levels and longer responses following test doses of apomorphine given at the end of the study. Although pragmatic concerns with the use of infusion pumps solutions and adverse effects limited the overall benefit afforded by the treatment, this kind of drug treatment may be useful in selected patients with severe parkinsonism and fluctuations.

AB - We assessed the clinical utility of apomorphine infusional therapy in patients with parkinsonism and motor fluctuations and sought evidence for alterations in drug response resulting from chronic treatment. Six patients with Parkinson's disease were treated for 3 months with s.c. infusions of apomorphine administered during waking hours. At the beginning and the end of the study, test doses of apomorphine (12.5-100 μg/kg) were administered to establish a dose-response curve. Over the study, the patients reported a significant improvement in the number of 'on' hours experienced per day and substantially reduced the dose and frequency of levodopa and other antiparkinsonian medications. No average change in apomorphine dose-response relationships or pharmacokinetics was observed during the study. However, two patients lowered the infusion rate during the 3-month observation and exhibited higher drug levels and longer responses following test doses of apomorphine given at the end of the study. Although pragmatic concerns with the use of infusion pumps solutions and adverse effects limited the overall benefit afforded by the treatment, this kind of drug treatment may be useful in selected patients with severe parkinsonism and fluctuations.

KW - Apomorhine

KW - Infusional therapy

KW - Parkinson's disease

KW - Sensitization

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0028830804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028830804&partnerID=8YFLogxK

U2 - 10.1002/mds.870100108

DO - 10.1002/mds.870100108

M3 - Article

C2 - 7885354

AN - SCOPUS:0028830804

VL - 10

SP - 37

EP - 43

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -